After the pandemic of COVID-19, neutralizing antibodies (NAbs) against SARS-CoV-2 have
been developed for the prophylactic and therapeutic purposes. However, few …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …

ABSTRACT Coronavirus disease 2019 (COVID-19) is an evolving global public health crisis
in need of therapeutic options. Passive immunization of monoclonal antibodies (mAbs) …

Most individuals infected with or vaccinated against COVID-19 develop antigenic
neutralizing immunoglobulin G (IgG) antibodies against the SARS-CoV-2 spike protein …

COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development
of therapeutic interventions. Due to their safety, specificity, and potential for rapid …

The magnitude and the quality of humoral responses against SARS-CoV-2 have been
associated with clinical outcome. Although the elicitation of humoral responses against …

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has caused a global pandemic. Early and accurate …

SARS-CoV-2 Omicron variant has presented significant challenges to current antibodies
and vaccines. Herein, we systematically compared the efficacy of 50 human monoclonal …

Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …